bioAffinity Technologies ...
(BIAFW)
undefined
undefined%
At close: undefined
0.80
167.20%
Pre-market Nov 19, 2024, 10:19 AM EST
Company Description
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.
The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells.
The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
bioAffinity Technologies Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Maria Zannes J.D. |
Contact Details
Address: No Address available No city data available, United States | |
| Website | http://www.bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAFW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W117 |
| ISIN Number | US09076W1172 |
| Employer ID | 46-5211056 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes J.D. | Founder, President, Chief Executive Officer & Director |
| J. Michael Edwards CPA, M.B.A. | Chief Financial Officer & Principal Accounting Officer |
| Xavier T. Reveles M.S. | Chief Operating Officer |
| Dallas J. Coleman | Vice President of sales |
| Dr. William Bauta Ph.D. | Chief Science Officer |
| Julie Anne Overton | Director of Communications |
| Steven Girgenti | Founder & Executive Chairman of the Board |
| Timothy P. Zannes J.D. | Executive Vice President, Secretary & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 09, 2024 | 424B3 | Filing |
| Nov 27, 2024 | S-1 | Filing |
| Nov 22, 2024 | 424B3 | Filing |
| Nov 22, 2024 | 424B3 | Filing |
| Nov 22, 2024 | 424B3 | Filing |
| Nov 22, 2024 | DEF 14A | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |